<DOC>
	<DOCNO>NCT02373150</DOCNO>
	<brief_summary>This study ass pharmacokinetics single repeat dos imeglimin healthy Japanese subject , safety tolerability single repeat dos imeglimin healthy Japanese subject .</brief_summary>
	<brief_title>Safety , Tolerability PK Imeglimin Japanese Volunteers</brief_title>
	<detailed_description>Combined single repeat dose group 3 escalate dos</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female Japanese subject , deem healthy basis clinical history , physical examination , ECG , vital sign , laboratory test blood urine Body mass index range 18.025.0 kg/m2 Willing use reliable contraception Able give fully inform write consent . Pregnant lactate woman , sexually active woman childbearing potential use reliable contraception Clinically relevant abnormal finding screen assessment Clinically significant vital sign outside acceptable range screen Clinically relevant abnormal medical history , surgery concurrent medical condition Acute chronic illness Estimated glomerular filtration rate le 80 mL/min/1.73 m2 Severe adverse reaction drug sensitivity trial medication component Significant food allergy ; vegetarian vegan Use vitamins , herbal medicine , overthecounter medication ( exception paracetamol [ acetaminophen ] ) within 7 day first dose trial medication , prescribe medication 14 day first dose trial medication Participation clinical trial unlicensed prescription medicine , loss 400 mL blood , within 3 month first dose trial medication Drug alcohol abuse Smoking 5 cigarette daily Possibility subject cooperate Positive test hepatitis B &amp; C , HIV Objection General Practitioner .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>